Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1973 1
1976 1
1988 1
1990 1
1992 1
1995 2
1999 1
2000 1
2001 4
2003 2
2004 3
2005 1
2006 3
2007 2
2008 3
2009 1
2010 5
2011 1
2012 14
2013 12
2014 17
2015 12
2016 12
2017 13
2018 25
2019 38
2020 40
2021 57
2022 43
2023 60
2024 23

Text availability

Article attribute

Article type

Publication date

Search Results

360 results

Results by year

Filters applied: . Clear all
Page 1
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study.
Johnson ML, Cho BC, Luft A, Alatorre-Alexander J, Geater SL, Laktionov K, Kim SW, Ursol G, Hussein M, Lim FL, Yang CT, Araujo LH, Saito H, Reinmuth N, Shi X, Poole L, Peters S, Garon EB, Mok T; POSEIDON investigators. Johnson ML, et al. J Clin Oncol. 2023 Feb 20;41(6):1213-1227. doi: 10.1200/JCO.22.00975. Epub 2022 Nov 3. J Clin Oncol. 2023. PMID: 36327426 Free PMC article. Clinical Trial.
PURPOSE: The open-label, phase III POSEIDON study evaluated tremelimumab plus durvalumab and chemotherapy (T + D + CT) and durvalumab plus chemotherapy (D + CT) versus chemotherapy alone (CT) in first-line metastatic non-small-cell lung cancer (mNSCLC). ...
PURPOSE: The open-label, phase III POSEIDON study evaluated tremelimumab plus durvalumab and chemotherapy (T + D + CT) and durvalumab …
POSEIDON groups and their distinct reproductive outcomes: Effectiveness and cost-effectiveness insights from real-world data research.
Esteves SC, Yarali H, Vuong LN, Conforti A, Humaidan P, Alviggi C. Esteves SC, et al. Best Pract Res Clin Obstet Gynaecol. 2022 Dec;85(Pt B):159-187. doi: 10.1016/j.bpobgyn.2022.05.003. Epub 2022 May 19. Best Pract Res Clin Obstet Gynaecol. 2022. PMID: 35725717 Review.
The Patient-Oriented Strategies Encompassing IndividualizeDOocyte Number (POSEIDON) criteria identify and classify the so-called 'low-prognosis' patients undergoing assisted reproductive technology (ART). ...Lastly, a predictive model has been developed and validated to es …
The Patient-Oriented Strategies Encompassing IndividualizeDOocyte Number (POSEIDON) criteria identify and classify the so-called 'low …
Management Strategies for POSEIDON Groups 3 and 4.
Haahr T, Dosouto C, Alviggi C, Esteves SC, Humaidan P. Haahr T, et al. Front Endocrinol (Lausanne). 2019 Sep 11;10:614. doi: 10.3389/fendo.2019.00614. eCollection 2019. Front Endocrinol (Lausanne). 2019. PMID: 31572298 Free PMC article. Review.
With the increasing delay in childbearing, POSEIDON group 4 seems to increase in numbers now in some centers constituting more than 50% of the total POSEIDON population, whereas group 3 patients constitute approximately 10%. ...Herein, we review the recent evidence …
With the increasing delay in childbearing, POSEIDON group 4 seems to increase in numbers now in some centers constituting more than 5 …
Update on the management of poor ovarian response in IVF: the shift from Bologna criteria to the Poseidon concept.
Drakopoulos P, Bardhi E, Boudry L, Vaiarelli A, Makrigiannakis A, Esteves SC, Tournaye H, Blockeel C. Drakopoulos P, et al. Ther Adv Reprod Health. 2020 Jul 31;14:2633494120941480. doi: 10.1177/2633494120941480. eCollection 2020 Jan-Dec. Ther Adv Reprod Health. 2020. PMID: 32844159 Free PMC article. Review.
The last decade has witnessed the attempts of the medical community to standardize diagnosis of POR with the developing of the Bologna Criteria and the subsequent evolution of the low prognosis patient elaborated in the POSEIDON classification. The aim of this article is t …
The last decade has witnessed the attempts of the medical community to standardize diagnosis of POR with the developing of the Bologna Crite …
Effects of Creatine Supplementation on Brain Function and Health.
Forbes SC, Cordingley DM, Cornish SM, Gualano B, Roschel H, Ostojic SM, Rawson ES, Roy BD, Prokopidis K, Giannos P, Candow DG. Forbes SC, et al. Nutrients. 2022 Feb 22;14(5):921. doi: 10.3390/nu14050921. Nutrients. 2022. PMID: 35267907 Free PMC article. Review.
Future Perspectives of POSEIDON Stratification for Clinical Practice and Research.
Humaidan P, La Marca A, Alviggi C, Esteves SC, Haahr T. Humaidan P, et al. Front Endocrinol (Lausanne). 2019 Jul 11;10:439. doi: 10.3389/fendo.2019.00439. eCollection 2019. Front Endocrinol (Lausanne). 2019. PMID: 31354620 Free PMC article. Review.
A total of 50% of patients undergoing IVF treatment has previously been estimated to fulfill the POSEIDON classification criteria; importantly, although the reproductive prognosis differs between patients, POSEIDON patients share the same characteristic of a low ova …
A total of 50% of patients undergoing IVF treatment has previously been estimated to fulfill the POSEIDON classification criteria; im …
The POSEIDON stratification - moving from poor ovarian response to low prognosis.
Roque M, Haahr T, Esteves SC, Humaidan P. Roque M, et al. JBRA Assist Reprod. 2021 Apr 27;25(2):282-292. doi: 10.5935/1518-0557.20200100. JBRA Assist Reprod. 2021. PMID: 33565297 Free PMC article. Review.
In this review, we aim to highlight the ongoing research for optimizing the prognosis in poor ovarian response patients. The newly introduced POSEIDON criteria argue that the first step is to move from a poor response to a poor prognosis concept, while improving identifica …
In this review, we aim to highlight the ongoing research for optimizing the prognosis in poor ovarian response patients. The newly introduce …
Poseidon and Caeneus: a case of pubertal gender inversion in Greek mythology.
Stamou MI, Armeni AK, Kazantzidis G, Georgopoulos NA, Markantes GK. Stamou MI, et al. Hormones (Athens). 2024 Jan 16. doi: 10.1007/s42000-023-00524-9. Online ahead of print. Hormones (Athens). 2024. PMID: 38225509 Review.
One of the most striking types of DSD described in many myths is gender transformation wherein a female becomes a male or vice versa. Herein, we present via the marvelous myth of Poseidon and Caeneus a case of pubertal gender inversion. A medical interpretation of the myth …
One of the most striking types of DSD described in many myths is gender transformation wherein a female becomes a male or vice versa. Herein …
360 results